MapLight Therapeutics, Inc. (MPLT) Stock: Price, Forecast & Analyst Target
MapLight Therapeutics, Inc. (MPLT) — MoonshotScore 46/100 (Fair band), calculated Nov 18, 2026. Price $6.42 (-3.46%), as of the Nov 19, 2026 trading session; market cap $357M.
Educational signal · not a buy or sell recommendation · How to read this
MapLight Therapeutics, Inc. · MPLT · NASDAQ
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders. Their pipeline includes treatments for schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, Parkinson's disease, and agitation-related disorders.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · MapLight Therapeutics (MPLT)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality and stalling growth, though the balance sheet is only middling, and the price trend has turned against it. Business Quality: Thin; Financial Safety: Okay; Valuation: Fair; Growth Durability: Shrinking; Momentum: Slipping.
- EPS beat 2 of the last 5 reports
- Altman Z 4.64 · Piotroski F 2
- ROE -63.8% · ROA -62.4% · current ratio 16.52 · earnings yield -69.8% · free-cash-flow yield -56.7%
Holding back: weak fundamentals, soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 44 | Weak | |
| 47 | Fair | |
| 44 | Weak | |
| 44 | Weak | |
| 46 | Fair | |
| 46 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.42 | |
| Change on the day | -3.46% | |
| Market capitalisation | $357M | — |
| Shares traded on the day | 416.1K |
Price & events
Other perspectives
Council score for MapLight Therapeutics (MPLT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is MapLight Therapeutics (MPLT), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MapLight Therapeutics, Inc. (MPLT) is listed on NASDAQ. It employs 133 people. The market values it at $357M.
What do the latest results show for MapLight Therapeutics (MPLT)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of the last 5 reports.
What are the financial strengths and risks for MapLight Therapeutics (MPLT)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z 4.64 · Piotroski F 2. Trailing ratios: ROE -63.8% · ROA -62.4% · current ratio 16.52 · earnings yield -69.8% · free-cash-flow yield -56.7%.
Data-derived red flags
- Negative return on equity (-63.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at MapLight Therapeutics (MPLT)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -4.74 · 0 analysts. Current published price targets run low $13.00 · high $46.00 · consensus $29.20 · median $28.00 against a quoted price of $6.42 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for MPLT.
Checked against the records this page reads, on the dates shown above.
How does MapLight Therapeutics compare with its peers?
Short answer
MapLight Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1382.75 Nov 18, 2026 | $1.23T | 98 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $286.01 Nov 18, 2026 | $506B | 83 5-pillar Nov 18, 2026 | |
| $272.70 Nov 18, 2026 | $656B | 83 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| MapLight Therapeutics (MPLT) — this page | $6.42 | $357M | 46 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $13.00 – $46.00
- Consensus target
- $29.20
- Median target
- $28.00
- Revenue estimate
- $0.00
- EPS estimate
- $-4.74
Consensus record · Captured .
Measured against a quoted price of $6.42 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MPLT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MPLT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
MapLight Therapeutics Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the MPLT research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for MPLT?
MPLT carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders.
Is MPLT a good stock to buy?
Stock Expert AI does not rate MPLT buy, sell or hold. MapLight Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MPLT stock price today?
The last price recorded for MapLight Therapeutics, Inc. (MPLT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MPLT price target?
The analyst consensus price target for MapLight Therapeutics, Inc. (MPLT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What revenue streams does MapLight Therapeutics, Inc. have in healthcare?
Currently, MapLight Therapeutics, as a clinical-stage company, does not have established revenue streams from marketed products. Its potential future revenue streams depend on the successful development and commercialization of its drug candidates.
What are the key factors to evaluate for MPLT?
MapLight Therapeutics, Inc. (MPLT) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. These partnerships could provide access to funding, expertise, and distribution networks, enhancing MapLight's growth prospects. Not financial advice.
How frequently does MPLT data refresh on this page?
MPLT's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MPLT's recent stock price performance?
MapLight Therapeutics, Inc. (MPLT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel neural circuit targeting platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MPLT overvalued or undervalued right now?
MapLight Therapeutics, Inc. (MPLT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com